Literature DB >> 21115235

Cell-specific expression of TLR9 isoforms in inflammation.

Kelly J McKelvey1, John Highton, Paul A Hessian.   

Abstract

Toll-like receptors (TLRs) are key pattern recognition receptors during an immune response. With five isoforms of human TLR9 described, we hypothesised that differential expression of TLR9 isoforms in different cell types would result in variable contributions to the overall input from TLR9 during inflammation. We assessed the molecular expression of the TLR9 isoforms, TLR9-A, -C and -D. In normal peripheral blood mononuclear cells, B-lymphocytes express ∼100-fold more TLR9-A transcript than monocytes or T-lymphocytes, which predominantly express the TLR9-C transcript. Switches in isoform predominance accompany B-lymphocyte development. TLR9 protein expression in rheumatoid inflammatory lesions reflected the TLR9 isoform expression by immune cells. Herein we suggest that B-lymphocytes and plasmacytoid dendritic cells contribute the ∼3-fold higher TLR9-A transcript levels observed in inflamed synovium when compared to subcutaneous rheumatoid nodules. In contrast, macrophages and T-lymphocytes contribute the ∼4-fold higher TLR9-C transcript levels seen in nodules, compared to synovia. From protein sequence, predictions of subcellular localisation suggest TLR9-B may locate to the mitochondria, whereas TLR9-D adopts an opposing orientation in the endoplasmic reticulum. Consistent with this, structure models raise the possibility of alternative ligands for the TLR9-B and TLR9-D variants. Our results highlight differences in the expression of human TLR9 isoforms in normal and inflamed tissues, with differing contributions to inflammation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115235     DOI: 10.1016/j.jaut.2010.11.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  14 in total

Review 1.  Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Authors:  Marcin Kortylewski; Dayson Moreira
Journal:  Cancer Immunol Immunother       Date:  2017-02-18       Impact factor: 6.968

2.  Increased expression of endosomal members of toll-like receptor family abrogates wound healing in patients with type 2 diabetes mellitus.

Authors:  Kanhaiya Singh; Neeraj K Agrawal; Sanjeev K Gupta; Gyanendra Mohan; Sunanda Chaturvedi; Kiran Singh
Journal:  Int Wound J       Date:  2015-01-14       Impact factor: 3.315

3.  Modified Genomic Self-DNA Influences In Vitro Survival of HT29 Tumor Cells via TLR9- and Autophagy Signaling.

Authors:  Ferenc Sipos; Anna L Kiss; Miklós Constantinovits; Zsolt Tulassay; Györgyi Műzes
Journal:  Pathol Oncol Res       Date:  2018-11-21       Impact factor: 3.201

4.  TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy.

Authors:  Chan Gao; Anna Kozlowska; Sergey Nechaev; Haiqing Li; Qifang Zhang; Dewan M S Hossain; Claudia M Kowolik; Peiguo Chu; Piotr Swiderski; Don J Diamond; Sumanta K Pal; Andrew Raubitschek; Marcin Kortylewski
Journal:  Cancer Res       Date:  2013-10-23       Impact factor: 12.701

5.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Authors:  Qifang Zhang; Dewan Md Sakib Hossain; Sergey Nechaev; Anna Kozlowska; Wang Zhang; Yong Liu; Claudia M Kowolik; Piotr Swiderski; John J Rossi; Stephen Forman; Sumanta Pal; Ravi Bhatia; Andrew Raubitschek; Hua Yu; Marcin Kortylewski
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

6.  Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action.

Authors:  Lisa K Stamp; Jody Hazlett; Rebecca L Roberts; Christopher Frampton; John Highton; Paul A Hessian
Journal:  Arthritis Res Ther       Date:  2012-06-08       Impact factor: 5.156

7.  Expression of Toll-like receptor -7 and -9 in B cell subsets from patients with primary Sjögren's syndrome.

Authors:  Marie Karlsen; Torbjørn Hansen; Hilde H Nordal; Johan G Brun; Roland Jonsson; Silke Appel
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

8.  The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum).

Authors:  Omkar Byadgi; Dinda Puteri; Jai-Wei Lee; Tsung-Chou Chang; Yan-Horn Lee; Chun-Yen Chu; Ta-Chih Cheng
Journal:  J Immunol Res       Date:  2014-06-02       Impact factor: 4.818

Review 9.  Toll-like receptor 9 in breast cancer.

Authors:  Jouko Sandholm; Katri S Selander
Journal:  Front Immunol       Date:  2014-07-22       Impact factor: 7.561

10.  Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?

Authors:  Erika Aurora Martínez-García; Maria Guadalupe Zavala-Cerna; Andrea Verónica Lujano-Benítez; Pedro Ernesto Sánchez-Hernández; Beatriz Teresita Martín-Márquez; Flavio Sandoval-García; Mónica Vázquez-Del Mercado
Journal:  Front Immunol       Date:  2018-07-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.